New therapies, including antibody-drug conjugates, are revolutionizing treatment and extending survival in advanced urothelial carcinoma. Although the side effects of these new options require careful monitoring and management, bladder-preserving curative treatment for advanced urothelial carcinoma may finally become a reality.
European urology focus. 2024 Jun 16 [Epub ahead of print]
Bernadett Szabados, Thomas Powles
Barts Cancer Institute, Queen Mary University of London, London, UK; Department of Urology, University College London Hospital NHS Foundation Trust, London, UK., Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: .